Insulet Gains 62.9% in a Year: What's Driving the Stock?

Core Viewpoint - Insulet Corporation (PODD) has shown significant growth, with shares increasing by 62.9% over the past year, outperforming the industry growth of 9.9% and the S&P 500's increase of 9.1% [1] Company Overview - Insulet develops and markets the Omnipod System, a continuous insulin delivery system for insulin-dependent diabetes, which includes the Omnipod and the next-generation Omnipod DASH [2] Revenue Segments - The company reports revenues from three segments: U.S. Omnipod, International Omnipod, and Drug Delivery, with the latter involving partnerships with pharmaceutical companies to deliver drugs using the Omnipod System [3] Growth Drivers - The share price growth is driven by the strong performance of the Omnipod 5 system, which is the only FDA-cleared, fully disposable pod-based automated insulin delivery (AID) system, expanding the addressable market to over 5.5 million people in the U.S. [4] - Omnipod 5 has maintained strong momentum in new customer acquisitions in the U.S., showing sequential and year-over-year growth in Q4 2024, contributing to overall revenue increases across all business segments [5] Market Expansion - Insulet has successfully launched Omnipod 5 in multiple countries, including France, the Netherlands, Italy, Denmark, Finland, Norway, Sweden, and Australia, with plans for further expansion into Belgium, Switzerland, Canada, and five additional markets in 2025 [6][7] Innovation Focus - The company is committed to consumer-focused innovation, recently announcing the limited market release of Omnipod Discover, a digital platform aimed at enhancing patient engagement and outcomes, alongside a broad innovation agenda for 2025 [8] Financial Estimates - The Zacks Consensus Estimate for Insulet's 2025 EPS has increased by 9.4% to $4.29, with an earnings yield of 1.6%, significantly higher than the industry's 0.3% [12]